europeanpharmaceuticalreviewApril 24, 2020
Tag: antibody , precision medicine , targeted drug delivery
Researchers have developed a novel method for delivering therapeutic proteins to precise targets within the body. Their solution was to encapsulate the proteins in acoustically sensitive carriers which, in response to ultrasound, release their payload to a target.
"When you expose the particle to ultrasound it opens a hole in the cell membrane that lasts for a couple of microseconds," said Scott Medina, assistant professor of biomedical engineering at Penn State. "We can use this temporary opening to deliver antibodies, which are attractive therapeutic molecules in precision medicine that cannot otherwise get inside cells." These antibodies could be emerging therapeutics for cancers, infectious disease and rheumatoid arthritis.
However, the team revealed that successfully encapsulating the antibodies was difficult, because the protein did not interact well with the fluorous liquid that makes up the interior of the particle. In order to combat this, Janna Sloand, Medina’s doctoral student and first author of the paper published in ACS Nano, suggested using a chemical mask to coat the protein and allowing it to interact with the fluorous liquid. They found the fluorous mask had the correct counterbalance or polarity and fluorine to maintain the folded state and bioactivity of the protein, while enabling it to interact with the fluorous liquid.
"We had a lot of challenges developing this new method," said Sloand. "The most difficult was figuring out what kind of chemicals could mask the protein. That was definitely my eureka moment when I saw that it worked."
The team now plan to explore how their ultrasound-programmable material could be used as a platform for image-guided delivery of therapeutic proteins and gene editing tools. They are already using the technology to deliver antibodies that can alter abnormal signalling pathways in tumour cells, turning off their malignant traits and delivering gene editing tools, like CRISPR constructs, to enable ultrasound-controlled genome engineering of cells in complex three-dimensional (3D) tissue microenvironments.
They highlighted that a key feature of their technology is that the ultrasound required is the same as that already employed for other applications in hospitals, potentially making implementation of their technology easier in future.
CPhI China 2020 To Be Postponed to Dec. 16-18th,
Register as Visitor to the 20th Edition of CPhI China!
-----------------------------------------------------------------------
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the articles,
please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: